147 related articles for article (PubMed ID: 24469564)
1. Chronic myeloid leukemia with hyperdiploidy: a case report with review of literature.
Belurkar S; Manohar C; Kurien A
Indian J Med Sci; 2013; 67(7-8):188-92. PubMed ID: 24469564
[TBL] [Abstract][Full Text] [Related]
2. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
3. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Xu Y; Wahner AE; Nguyen PL
Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
[TBL] [Abstract][Full Text] [Related]
4. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
6. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
7. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
[TBL] [Abstract][Full Text] [Related]
8. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
[TBL] [Abstract][Full Text] [Related]
10. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
Zaccaria A; Valenti AM; Donti E; Gozzetti A; Ronconi S; Spedicato F
Haematologica; 2007 Apr; 92(4):564-5. PubMed ID: 17488671
[TBL] [Abstract][Full Text] [Related]
11. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
15. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
16. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia.
Van Den Akker J; Coppo P; Portnoï MF; Barbu V; Bories D; Gorin NC
Leuk Lymphoma; 2007 Sep; 48(9):1858-65. PubMed ID: 17786726
[TBL] [Abstract][Full Text] [Related]
18. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
19. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]